Overview
Iberdomide (CC-220) has been used in trials studying the treatment of Systemic Lupus Erythematosus.
Background
Iberdomide (CC-220) has been used in trials studying the treatment of Systemic Lupus Erythematosus.
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/03/26 | Phase 1 | Not yet recruiting | |||
2025/03/25 | Phase 2 | Not yet recruiting | |||
2025/01/21 | Phase 1 | Recruiting | |||
2024/07/24 | Phase 1 | Recruiting | Omar Nadeem, MD | ||
2024/06/18 | Phase 1 | Recruiting | |||
2024/04/04 | Phase 1 | Not yet recruiting | Thomas Martin, MD | ||
2024/01/30 | Phase 1 | Suspended | |||
2024/01/22 | Phase 3 | Recruiting | University of Heidelberg Medical Center | ||
2024/01/22 | Phase 1 | Recruiting | |||
2023/12/22 | Phase 2 | Recruiting |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||